Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
C$1.50
+24.0%
C$2.12
C$1.02
C$31.50
C$64.59M1.365,082 shs5,930 shs
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
C$0.00
C$0.15
C$1.23
C$15.64M0.19135,475 shs167,044 shs
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
C$0.26
-3.8%
C$0.26
C$0.15
C$0.53
C$52.28MN/A644,760 shs384,329 shs
Promis Neurosciences stock logo
PMN
Promis Neurosciences
$0.43
-1.5%
$0.52
$0.42
$2.37
$13.93M-0.181,488 shs103,918 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
0.00%+11.01%-50.61%-68.57%-96.08%
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
0.00%0.00%0.00%0.00%0.00%
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
0.00%0.00%0.00%0.00%0.00%
Promis Neurosciences stock logo
PMN
Promis Neurosciences
0.00%-3.58%-3.14%-20.54%-74.13%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Promis Neurosciences stock logo
PMN
Promis Neurosciences
3.3877 of 5 stars
3.55.00.00.00.00.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
4.00
Strong BuyN/AN/A
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
0.00
N/AN/AN/A
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
0.00
N/AN/AN/A
Promis Neurosciences stock logo
PMN
Promis Neurosciences
3.00
Buy$4.50908.97% Upside

Current Analyst Ratings Breakdown

Latest ATE, EMH, APS, and PMN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2025
Promis Neurosciences stock logo
PMN
Promis Neurosciences
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$3.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
N/AN/AC$0.91 per share1.60C($0.92) per shareN/A
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
C$9.71M0.00N/A0.61C$0.49 per share0.00
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
C$13.02M4.02C$0.33 per share0.78C$0.40 per share0.64
Promis Neurosciences stock logo
PMN
Promis Neurosciences
N/AN/AN/AN/A$0.50 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
-C$154.69M-C$5.02N/AN/AN/A1,017.48%-136.29%N/A
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
-C$18.24M-C$0.35N/AN/AN/AN/A-52.72%-19.13%N/A
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/A-C$0.70N/AN/AN/AN/AN/AN/A
Promis Neurosciences stock logo
PMN
Promis Neurosciences
$2.78M-$0.05N/AN/AN/AN/A-186.19%-98.56%8/6/2025 (Estimated)

Latest ATE, EMH, APS, and PMN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Promis Neurosciences stock logo
PMN
Promis Neurosciences
-$0.14-$0.21-$0.07-$0.21N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
N/A0.39%N/AN/AN/A
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
C$0.05N/AN/AN/A N/A
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/AN/AN/AN/AN/A
Promis Neurosciences stock logo
PMN
Promis Neurosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
-117.37
1.05
5.41
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
0.29
10.06
9.58
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
35.45
2.97
2.61
Promis Neurosciences stock logo
PMN
Promis Neurosciences
N/A
3.36
3.36

Institutional Ownership

CompanyInstitutional Ownership
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
15.10%
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
N/A
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/A
Promis Neurosciences stock logo
PMN
Promis Neurosciences
50.13%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
3143.06 millionN/ANot Optionable
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
1153.01 millionN/ANot Optionable
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
161205.03 millionN/ANot Optionable
Promis Neurosciences stock logo
PMN
Promis Neurosciences
532.69 million30.69 millionNot Optionable

Recent News About These Companies

ProMIS Neurosciences reports FY24 EPS 11c vs. ($1.07) last year
ProMIS Neurosciences doses first patiets in Phase 1b PRECISE-AD trial
ProMIS Neurosciences seperates from COO Malenfant, terminates COO position
ProMIS Neurosciences anticipates PRECISE-AD interim patient data in 1H26

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aptose Biosciences stock logo

Aptose Biosciences TSE:APS

C$1.50 +0.29 (+23.97%)
As of 01:27 PM Eastern

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Antibe Therapeutics stock logo

Antibe Therapeutics TSE:ATE

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Emerald Health Therapeutics stock logo

Emerald Health Therapeutics CVE:EMH

C$0.26 -0.01 (-3.77%)
As of 04/26/2021

Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis for medical purpose in Canada. The company is also involved in developing natural health products. It offers dried cannabis strains, pre-rolls, and cannabis oil products to its medical patients. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.

Promis Neurosciences stock logo

Promis Neurosciences NASDAQ:PMN

$0.43 -0.01 (-1.46%)
As of 02:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.